Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate ... ECGs, clinical laboratory tests, physical examinations, and visual analogue mood ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...

Effects on clinical parameters including days with lesions ... into Phase 1b studies after each long-acting helicase-primase inhibitor candidate exceeded the company’s target PK profiles in Phase 1a ...

Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to ...

Data from the ongoing Phase 1/2 clinical trial (NCT05914116) in patients with heavily pre-treated castration-resistant ...

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress ...

Moderna Inc (NASDAQ:MRNA) saw its stock rise 3.8% after announcing that its experimental flu vaccine, mRNA-1010, delivered ...

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging ...

SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented ...